Lisata Therapeutics Inc (LTS:0HS8)
$ 3.58 0.148 (4.31%) Market Cap: 29.91 Mil Enterprise Value: -13.27 Mil PE Ratio: 0 PB Ratio: 0.70 GF Score: 33/100

Q4 2019 Caladrius Biosciences Inc Earnings Call Transcript

Mar 05, 2020 / 09:30PM GMT
Release Date Price: $44.25
Operator

Welcome to the Caladrius Bioscience Fourth Quarter and Full Year 2019 Financial Results and Business Update Conference call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, March 5, 2020.

I'll now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Good afternoon and thank you all for participating in today's call. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; and Joseph Talamo, Chief Financial Officer.

Earlier today, we issued a news release announcing our 2019 fourth quarter and full year financial results. If you have not received this news release or would like to be added to the company's email distribution list, please e-mail me at [email protected].

Before we begin, I'll remind you that the comments made by management during this conference call will contain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot